全文获取类型
收费全文 | 25098篇 |
免费 | 2636篇 |
国内免费 | 951篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 270篇 |
妇产科学 | 176篇 |
基础医学 | 1212篇 |
口腔科学 | 193篇 |
临床医学 | 1844篇 |
内科学 | 2959篇 |
皮肤病学 | 356篇 |
神经病学 | 1923篇 |
特种医学 | 269篇 |
外国民族医学 | 8篇 |
外科学 | 1101篇 |
综合类 | 2827篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 1281篇 |
眼科学 | 194篇 |
药学 | 9899篇 |
12篇 | |
中国医学 | 1685篇 |
肿瘤学 | 2408篇 |
出版年
2024年 | 33篇 |
2023年 | 517篇 |
2022年 | 650篇 |
2021年 | 1058篇 |
2020年 | 1012篇 |
2019年 | 1075篇 |
2018年 | 1077篇 |
2017年 | 1207篇 |
2016年 | 1091篇 |
2015年 | 1112篇 |
2014年 | 1875篇 |
2013年 | 2984篇 |
2012年 | 1654篇 |
2011年 | 1682篇 |
2010年 | 1360篇 |
2009年 | 1094篇 |
2008年 | 1012篇 |
2007年 | 1063篇 |
2006年 | 869篇 |
2005年 | 763篇 |
2004年 | 610篇 |
2003年 | 583篇 |
2002年 | 403篇 |
2001年 | 395篇 |
2000年 | 312篇 |
1999年 | 249篇 |
1998年 | 227篇 |
1997年 | 203篇 |
1996年 | 207篇 |
1995年 | 191篇 |
1994年 | 162篇 |
1993年 | 191篇 |
1992年 | 186篇 |
1991年 | 138篇 |
1990年 | 133篇 |
1989年 | 107篇 |
1988年 | 120篇 |
1987年 | 80篇 |
1986年 | 92篇 |
1985年 | 130篇 |
1984年 | 115篇 |
1983年 | 82篇 |
1982年 | 93篇 |
1981年 | 61篇 |
1980年 | 71篇 |
1979年 | 57篇 |
1978年 | 63篇 |
1977年 | 56篇 |
1976年 | 47篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Forced normalization (FN) is a unique phenomenon that is often seen in the treatment of epilepsy. FN is characterized by abnormal mental behavior and disordered emotions in epilepsy patients despite a significantly improved electroencephalogram and successful seizure control; the occurrence of FN seriously affects patients’ quality of life. The causes of FN include antiseizure medications (ASMs), epilepsy surgery and vagus nerve stimulation, with ASMs being the most common cause. However, with the timely reduction or discontinuation of ASMs and the use of antipsychotic drugs, the overall prognosis is good. Here, we perform an extensive review of the literature pertaining to FN, including its epidemiology, possible mechanisms, clinical features, treatment and prognosis. 相似文献
92.
该文对某医院的注射剂避光药品管理进行研究,在该次研究中发现,某医院共有药品1 500多种,其中,避光注射剂的种类就达到了248种。由此可以看出,在医院的药品之中,避光注射剂的有着比较多的种类和数量。应该不断强化对注射剂避光药品的管理,这样才可以让这一类的注射剂发挥出其原有的作用,有效避免因避光不佳而导致的药物失效甚至一些临床不良反应的情况出现。 相似文献
93.
Daisuke Ishibashi Takeshi Ishikawa Satoshi Mizuta Hiroya Tange Takehiro Nakagaki Tsuyoshi Hamada Noriyuki Nishida 《Neurotherapeutics》2020,17(4):1836
The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrPC) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the “hot spot,” stabilizes the structure of PrPC and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrP in vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrPSc levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrPSc accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate that in silico drug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00903-9) contains supplementary material, which is available to authorized users. 相似文献
94.
Opioid use frequency in early axial spondyloarthritis in Finland – a pharmacoepidemic register study
《Joint, bone, spine : revue du rhumatisme》2022,89(3):105302
ObjectivesTo evaluate opioid use among incident axial spondyloarthritis (axSpA) patients compared to general population.MethodsFrom the national register, we identified all adult patients with axSpA (ICD-10 codes M45-46), who between 2010 and 2014 (index date, ID) were for the first time granted special reimbursement for any disease-modifying antirheumatic drugs (DMARDs). Three matched population controls were identified for each patient. Drug purchases were evaluated between 2009–2015, and opioid use was analyzed for one year before and after the ID. The Defined Daily Dose (DDD) was used as a tool to assess the opioid consumption before and after the biological (b) DMARD initiation.ResultsWe identified 3577 axSpA patients and 10,573 controls. Of these patients, 97.2% started a conventional synthetic (cs) DMARD during a year after ID and 23.4% switched later to a self-injected bDMARD between the ID and 31 Dec 2015 (median follow-up 3.4 years). Opioids were purchased at least once by 29.8% and 21.7% of the patients in the years before and after the ID, respectively, compared to 8.1% and 7.8% of the controls. The proportion of opioid-using patients was greatest during the last quarter before the ID [relative risk (RR) 4.72 (95% CI 4.14 to 5.39)] compared to controls, and it remained higher [RR 2.84 (2.59 to 3.11)] also after the start of csDMARDs. DDD of opioid consumption decreased from 7.7 to 1.6/1000 inhabitants after bDMARD initiation.ConclusionConsiderably more axSpA patients than population controls used opioids. The opioid consumption by dose decreased clearly after bDMARD initiation. 相似文献
95.
96.
《中国现代医生》2020,58(32):103-106
目的 研究培美曲塞与多西他赛在晚期非小细胞肺癌靶向治疗失败后挽救化疗中的应用效果。方法 筛选2018 年1 月~2020 年1 月本院的60 例晚期非小细胞肺癌靶向治疗失败后挽救化疗的患者作为研究对象,依据患者选择的药物种类分为观察组和对照组,每组各30 例,对照组采用多西他赛治疗,观察组予以培美曲塞治疗,对比分析两组的近期治疗效果、生存质量评分和毒副反应发生情况。结果 观察组病症控制率为66.67%,对照组病症控制率为36.67%,观察组病症控制效果更好;观察组生存质量评分为(65.2±3.4)分,对照组生存质量评分为(51.7±4.6)分,两组比较差异有统计学意义(t=12.926,P=0.000);观察组各项毒副反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论 在晚期非小细胞肺癌靶向治疗失败后进行挽救化疗中选用培美曲塞有更好的治疗效果,可以较好的进行临床治疗,改善患者的生活质量,且产生的毒副反应较少,在实际临床中的应用价值较高。 相似文献
97.
目的:通过文献计量学分析方法,阐述并分析肺癌靶向治疗的研究热点与趋势。方法:文章检索了万方数据库、Web of Science、SooPAT(中国专利)数据库近10年来国内外肺癌靶向治疗的相关文献,以文献计量学方法,分析并归类了肺癌靶向治疗的研究热点与时效变迁的趋势。结果:在万方数据库3 744篇肺癌靶向治疗的中文文章中,发现作用于表皮生长因子受体基因突变位点的分子靶向药物-吉非替尼治疗非小细胞肺癌的研究是中国学者近10年的主要研究热点;在近10年Web of Science数据库中检索到的810篇英文文章及参考文献显示,西妥昔单抗、贝伐单抗、纳武单抗、吉非替尼、厄洛替尼和环唑替尼为这10年肺癌治疗领域靶向治疗的热点药物,而多种靶向药物的联合治疗、晚期非小细胞肺癌的靶向治疗效果和肺癌靶向治疗后的脑转移也成为近5年该领域的国际关注热点;中国肺癌靶向治疗领域的254项有权专利的分析显示,申报了专利的主要药物包括酸敏感的吉非替尼-氟硼二吡咯衍生物、顺铂抗肺癌主动靶向隐形类脂质体等。结论:文章采用文献计量学的量化分析技术,呈现出近10年肺癌靶向治疗已成为该领域专业研究者持续关注的热点,而如何选择正确的靶向药物或药物组合方案来解决肺癌治疗中的耐药性问题,同时最大程度地减少患者的不良反应,以延长患者的生存率,应是未来集中研究的方向。 相似文献
98.
99.
Cristiano Colalto 《Drug development research》2020,81(8):950-968
COVID-19 is a novel coronavirus disease with a higher incidence of bilateral pneumonia and pleural effusion. The high pulmonary tropism and contagiousness of the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have stimulated new approaches to combat its widespread diffusion. In developing new pharmacological strategies, the chemical characteristic of volatility can add therapeutic value to the hypothetical drug candidate. Volatile molecules are characterized by a high vapor pressure and are consequently easily exhaled by the lungs after ingestion. This feature could be exploited from a pharmacological point of view, reaching the site of action in an uncommon way but allowing for drug delivery. In this way, a hypothetical molecule for COVID-19 should have a balance between its lung exhalation characteristics and both antiviral and anti-inflammatory pharmacological action. Here, the feasibility, advantages, and disadvantages of a therapy based on oral administration of possible volatile drugs for COVID-19 will be discussed. Both aerosolized antiviral therapy and oral intake of volatile molecules are briefly reviewed, and an evaluation of 1,8-cineole is provided in view of a possible clinical use and also for asymptomatic COVID-19. 相似文献
100.